1. Why the interest in SEBs? • Biologics are effective treatments for complex chronic conditions • Patent expiries – more biosimilars will be available • need to…

Slide 1 SEBs – A Public Payer Perspective Judy McPhee, Executive Director Nova Scotia Pharmaceutical Services Slide 2 Why the interest in SEBs? Biologics are effective…

Slide 1 . Tanya Potashnik: A/Director, Policy and Economic Analysis October, 2013 Patented Medicine Prices Review Board CPI Initiative Slide 2 CPI-Initiative - Background…

Making therapeutic decisions with ongoing drug shortages Dr. Roland Halil, BSc(Hon), BScPharm, ACPR, PharmD Pharmacist, Bruyere Academic Family Health Team Assistant Professor,…

Cardiology Review Short & Snappy Cardiology Review (One Hour or its Free!) Roland Halil, BSc(Hon), BScPharm, ACPR, PharmD Bruyere FHT, Ottawa, ON Dept of Family Medicie,…

Patented Medicine Prices Review Board . Tanya Potashnik: A/Director, Policy and Economic Analysis October, 2013 Patented Medicine Prices Review Board CPI Initiative 1 CPI-Initiative…